“All patients who were response evaluable and had at least one post-baseline scan exhibited tumor shrinkage, and there were no patients that exhibited disease progression as their best overall response to treatment.” Ferdinandos Skoulidis, MD, PhD, MRCP, an associate professor...
Research ArticleArticles in Press109560August 07, 2026Open accessClinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world studyLaura Masfarra ∙ Ana Sofia De Freitas Matos Parreirab ∙ Natalia Castroc ∙ … ∙ Claudia Miquela ∙ Nil...
AbstractObjective The goal of the current study was to assess the frequency of KRAS mutation subtypes in a cohort of advanced non-small cell lung cancer (NSCLC). More importantly, we present the clinical characteristics, treatment profile, as well as overall survival...
KRAS mutations, particularly KRAS G12C, pose significant therapeutic challenges in non-small cell lung cancer (NSCLC) due to limited inhibitor efficacy and rapid resistance. Drug repurposing offers a time and cost-effective strategy to identify alternative therapeutic options targeting KRAS-driven signalling. A...
You are reading this latest preprint version Therapeutic vaccines for non-small cell lung cancer (NSCLC) are almost invariably designed against global HLA supertypes, yet the immunogenetics of Southeast Asian patients diverges substantially from the largely European allele sets underlying them....
Benjamin Herzberg, MD In an interview with Targeted OncologyTM, Benjamin Herzberg, MD, of the Division of Hematology/Oncology at Columbia University Irving Medical Center, outlined the most pressing unmet needs in KRAS-mutant non–small cell lung cancer (NSCLC), discussed how he sequences...
GFH375 becomes first oral KRAS G12D inhibitor entering Phase III trials for NSCLC. GenFleet Therapeutics' Kylin-Flight 01 study shows promising progress China-based GenFleet Therapeutics (Shanghai) Inc. (HKEX: 02595) announced on August 10 that the first patient has been dosed in...
Treatment of NSCLC KRAS G12C mutant tumors with the allele-selective sotorasib and adagrasib inhibitors is invariably associated with acquired resistance. The MUC1-encoded oncogenic M1C protein is necessary for self-renewal of NSCLC KRAS mutant cells. We report that treatment of NSCLC...
The FDA has granted breakthrough therapy designation to olomorasib (LY3537982) as a monotherapy for adult patients with advanced pancreatic cancer harboring a KRAS G12C mutation who have received at least 1 prior systemic therapy, according to a news release from...
